United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Search entities
Discover all 39,707 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2314,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "722b5f75-7671-418c-aaec-038b9fce97d8",
"title": "AZZ Inc (AZZ) Q4 2024 Earnings Call Transcript Highlights: Strong Performance and Strategic Acquisitions Set the Stage",
"description": "Total Sales: $1.54 billion, up 16.2% year-over-year.Metal Coatings Sales: $656 million, increased by 3%.Precor Metal Sales: $881 million, up 28.4%.Adjusted EBI",
"keywords": "GuruFocus, Article, News, GuruFocus Research, AZZ",
"snippet": "Release Date: April 22, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: Good mo...",
"url": "https://www.gurufocus.com/news/2415209/azz-inc-azz-q4-2024-earnings-call-transcript-highlights-strong-performance-and-strategic-acquisitions-set-the-stage",
"image_url": "https://static.gurufocus.com/logos/0C000006T0.png?5",
"language": "en",
"published_at": "2024-04-23T07:03:15.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZZ",
"name": "AZZ Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 89.234314,
"sentiment_score": 0.57952,
"highlights": [
{
"highlight": "A: (Philip Schlom - <em>AZZ</em> <em>Inc</em> - Chief Financial Officer) We operate with pretty low cash balances and use excess cash to reduce the borrowings on the revolver. We have a $400 million revolver with about $355 million in capacity at the end of the year.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "(Thomas Ferguson - <em>AZZ</em> <em>Inc</em> - President & Chief Executive Officer) There are a couple of potential galvanizing opportunities that have popped up that are the kind of bolt-on one-off sites that our team likes to look at. We would fund those off of the revolver.\n\nQ: Got it.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "A: (Thomas Ferguson - <em>AZZ</em> <em>Inc</em> - President & Chief Executive Officer) These are typically in the $10 million to $20 million revenue side. So and usually they're going to have save three or four? Well, yes, probably $3 million or $4 million of EBITDA. We tend to pay roughly six times. So that that's what we consider bolt-on.",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "A: (Thomas Ferguson - <em>AZZ</em> <em>Inc</em> - President & Chief Executive Officer) We've taken the flag down that we were out there in acquisition mode.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "A: (Thomas Ferguson - <em>AZZ</em> <em>Inc</em> - President & Chief Executive Officer) Yes, I think we still in our normal organic growth, particularly on the Metal Coatings side, tends to run with GDP. So when we can get a couple of acquisitions and that's going to going to add another 5%or 6% on a full year run rate basis.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "A: (Thomas Ferguson - <em>AZZ</em> <em>Inc</em> - President & Chief Executive Officer) Thanks.\n\nQ: Good morning, guys, and congratulations on another good quarter. And I'd like to start with the revenue profile.",
"sentiment": 0.9337,
"highlighted_in": "main_text"
},
{
"highlight": "A: (Thomas Ferguson - <em>AZZ</em> <em>Inc</em> - President & Chief Executive Officer) That's a good point, John, I think on the on the Metal Coatings side, you get an earlier start, it kind of depends on what. Yes.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "A: (David Nark - <em>AZZ</em> <em>Inc</em> - Senior Vice President of Marketing, Communications and Investor Relations) Yes, John, this is Dave. I think as you look at it, there's a couple of areas in the end markets.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "A: (Thomas Ferguson - <em>AZZ</em> <em>Inc</em> - President & Chief Executive Officer) Yes, I think we've always tried to talk about how we I've tried to differentiate our value pricing versus zinc, but it does help zinc has been trending up. And so as things trends up. That tends to help support our price levels.",
"sentiment": 0.9217,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AZZ</em> <em>Inc</em> (<em>AZZ</em>) Q4 2024 Earnings Call Transcript Highlights: Strong Performance and Strategic Acquisitions Set the Stage",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "2914e4d5-1985-4eb8-a5e2-ab4543f291f3",
"title": "Q4 2023 Supercom Ltd Earnings Call Transcript",
"description": "Apr 22, 2024 / 12:30PM GMTOperator Ladies and gentlemen, good morning, and welcome to SuperCom's Fourth Quarter and Year End 2023 Financial Results and Corporat",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:SPCB",
"snippet": "Apr 22, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nLadies and gentlemen, good morning, and welcome to SuperCom's Fourth Quarter and Year End 2023 Financial Results and Cor...",
"url": "https://www.gurufocus.com/news/2415173/q4-2023-supercom-ltd-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-23T05:00:28.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SPCB",
"name": "SuperCom Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 145.8573,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Q4 2023 <em>Supercom</em> <em>Ltd</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "6ddbdd4f-69d6-4f4f-b157-6ed5c7865996",
"title": "Q4 2024 Sify Technologies Ltd Earnings Call Transcript",
"description": "Apr 22, 2024 / 12:30PM GMTOperator Good morning, everyone, and welcome to Sify Technologies financial results for the fourth quarter and fiscal year 2023 to 202",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NAS:SIFY",
"snippet": "Apr 22, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nGood morning, everyone, and welcome to Sify Technologies financial results for the fourth quarter and fiscal year 2023 t...",
"url": "https://www.gurufocus.com/news/2415171/q4-2024-sify-technologies-ltd-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-04-23T05:00:26.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SIFY",
"name": "Sify Technologies Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 97.517166,
"sentiment_score": 0.570667,
"highlights": [
{
"highlight": "Apr 22, 2024 / 12:30PM GMT\n\nOperator\n\n\n\nGood morning, everyone, and welcome to <em>Sify</em> <em>Technologies</em> financial results for the fourth quarter and fiscal year 2023 to 2024. (Operator Instructions) Please note this conference is being recorded.\n\n\n\nI will now turn the conference over to your host, Praveen Krishna. Praveen, over to you.",
"sentiment": 0.802,
"highlighted_in": "main_text"
},
{
"highlight": "Praveen Krishna - <em>Sify</em> <em>Technologies</em> Ltd - IR and Public Relations\n\n\n\nThank you, and good morning, Jenny. I would like to extend a warm welcome to all of our participants on behalf of <em>Sify</em> <em>Technologies</em> <em>Limited</em>. I'm joined on the call today by my Chairman, Raju Vegesna; my Executive Director and Group CFO, Mr.",
"sentiment": 0.91,
"highlighted_in": "main_text"
},
{
"highlight": "Q4 2024 <em>Sify</em> <em>Technologies</em> Ltd Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "a95c5b3a-30bc-439c-a411-c7d1643cd24a",
"title": "Bank of Hawaii Corp (BOH) (Q1 2024) Earnings Call Transcript Highlights: Navigating Through Economic Shifts",
"description": "Net Interest Income: $113.9 million, a decrease of $1.8 million from the previous quarter.Net Interest Margin: Declined by two basis points from the previous q",
"keywords": "GuruFocus, Article, News, GuruFocus Research, BOH",
"snippet": "Release Date: April 22, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: Hi, goo...",
"url": "https://www.gurufocus.com/news/2415208/bank-of-hawaii-corp-boh-q1-2024-earnings-call-transcript-highlights-navigating-through-economic-shifts",
"image_url": "https://static.gurufocus.com/logos/0C000006U6.png?5",
"language": "en",
"published_at": "2024-04-23T07:02:59.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "BHWIL",
"name": "BANK OF HAWAII CORP",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 117.54446,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Bank</em> <em>of</em> <em>Hawaii</em> <em>Corp</em> (BOH) (Q1 2024) Earnings Call Transcript Highlights: Navigating Through Economic Shifts",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "0661d301-1841-4016-8b23-e8c780794b34",
"title": "Cadence Design Systems Inc (CDNS) Q1 2024 Earnings Call Transcript Highlights: Robust Financial Performance and Strategic Insights",
"description": "Revenue: Q1 total $1.09 billion.Backlog: Record Q1 backlog of approximately $6 billion.GAAP Operating Margin: 24.8% for Q1.Non-GAAP Operating Margin: 37.8% for",
"keywords": "GuruFocus, Article, News, GuruFocus Research, CDNS",
"snippet": "Release Date: April 22, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: Can you...",
"url": "https://www.gurufocus.com/news/2415206/cadence-design-systems-inc-cdns-q1-2024-earnings-call-transcript-highlights-robust-financial-performance-and-strategic-insights",
"image_url": "https://static.gurufocus.com/logos/0C0000072W.png?5",
"language": "en",
"published_at": "2024-04-23T07:02:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "CDNS",
"name": "Cadence Design Systems, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 144.082,
"sentiment_score": 0.367467,
"highlights": [
{
"highlight": "Wall, Senior VP & CFO of <em>Cadence</em> <em>Design</em> <em>Systems</em>, explained that the company anticipates a significant portion of revenue to be more second-half weighted due to the recent launch of new hardware systems. He highlighted that upfront revenue, which was 20% in Q1 2023, is only 10% this year, but is expected to be around 17.5% for the full year.",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "These insights from the Q&A session of <em>Cadence</em> <em>Design</em> <em>Systems</em>' earnings call provide a comprehensive view of the company's strategic directions, particularly in adapting to technological advancements and market dynamics.\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Cadence</em> <em>Design</em> <em>Systems</em> <em>Inc</em> (CDNS) Q1 2024 Earnings Call Transcript Highlights: Robust Financial Performance and Strategic Insights",
"sentiment": 0.34,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "5a5780e2-3036-43a4-b55e-fcb49f144b7e",
"title": "Truist Financial Corp (TFC) (Q1 2024) Earnings Call Transcript Highlights: Key Financial Metrics and Strategic Insights",
"description": "Net Income Available to Common Shareholders: $1.2 billionEarnings Per Share (EPS): $0.90Adjusted Net Income from Continuing Operations: $0.80 per shareAdjusted",
"keywords": "GuruFocus, Article, News, GuruFocus Research, TFC",
"snippet": "Release Date: April 22, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: How doe...",
"url": "https://www.gurufocus.com/news/2415205/truist-financial-corp-tfc-q1-2024-earnings-call-transcript-highlights-key-financial-metrics-and-strategic-insights",
"image_url": "https://static.gurufocus.com/logos/0C000006V9.png?5",
"language": "en",
"published_at": "2024-04-23T07:01:46.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TFC",
"name": "Truist Financial Corporation",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 55.381218,
"sentiment_score": 0.1366,
"highlights": [
{
"highlight": "A: Michael Baron Maguire, Senior EVP & CFO of <em>Truist</em> <em>Financial</em> <em>Corporation</em>, explained that the rate environment is considered in their framework, which remains committed to maintaining a relative capital position and replacing earnings from TIH.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Truist</em> <em>Financial</em> Corp (TFC) (Q1 2024) Earnings Call Transcript Highlights: Key Financial Metrics and Strategic Insights",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "7845e16b-ca40-4efe-a052-0bb249d1f177",
"title": "Verizon Communications Inc (VZ) Q1 2024 Earnings Call Transcript Highlights: Strong Wireless and Broadband Growth Amidst Strategic Shifts",
"description": "Wireless Service Revenue Growth: Increased by 3.3%Adjusted EBITDA: $12.1 billion, up 1.4% year-over-yearFree Cash Flow: $2.7 billion, up over 16% from Q1 2023P",
"keywords": "GuruFocus, Article, News, GuruFocus Research, VZ",
"snippet": "Release Date: April 22, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: Hans, m...",
"url": "https://www.gurufocus.com/news/2415204/verizon-communications-inc-vz-q1-2024-earnings-call-transcript-highlights-strong-wireless-and-broadband-growth-amidst-strategic-shifts",
"image_url": "https://static.gurufocus.com/logos/0C000009HV.png?5",
"language": "en",
"published_at": "2024-04-23T07:01:34.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "VZ.BA",
"name": "Verizon Communications Inc.",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Communication Services",
"match_score": 101.53196,
"sentiment_score": 0.7096,
"highlights": [
{
"highlight": "<em>Verizon</em> <em>Communications</em> <em>Inc</em> (VZ) Q1 2024 Earnings Call Transcript Highlights: Strong Wireless and Broadband Growth Amidst Strategic Shifts",
"sentiment": 0.7096,
"highlighted_in": "title"
}
]
},
{
"symbol": "VZ.SN",
"name": "Verizon Communications Inc.",
"exchange": null,
"exchange_long": null,
"country": "cl",
"type": "equity",
"industry": "Communication Services",
"match_score": 101.52993,
"sentiment_score": 0.7096,
"highlights": [
{
"highlight": "<em>Verizon</em> <em>Communications</em> <em>Inc</em> (VZ) Q1 2024 Earnings Call Transcript Highlights: Strong Wireless and Broadband Growth Amidst Strategic Shifts",
"sentiment": 0.7096,
"highlighted_in": "title"
}
]
},
{
"symbol": "VZ",
"name": "Verizon Communications Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 101.53021,
"sentiment_score": 0.7096,
"highlights": [
{
"highlight": "<em>Verizon</em> <em>Communications</em> <em>Inc</em> (VZ) Q1 2024 Earnings Call Transcript Highlights: Strong Wireless and Broadband Growth Amidst Strategic Shifts",
"sentiment": 0.7096,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "9bebddbe-5042-4a58-bfe4-e57c80cd0e70",
"title": "Washington Trust Bancorp Inc (WASH) Q1 2024 Earnings Call Transcript Highlights: Key Financial Metrics and Strategic Insights",
"description": "Net Income: $10.9 millionEarnings Per Share (EPS): $0.64 per diluted shareNet Interest Income: $31.7 million, down $1 million or 3%Interest Margin: 1.84%, down",
"keywords": "GuruFocus, Article, News, GuruFocus Research, WASH",
"snippet": "Release Date: April 22, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: Can you...",
"url": "https://www.gurufocus.com/news/2415202/washington-trust-bancorp-inc-wash-q1-2024-earnings-call-transcript-highlights-key-financial-metrics-and-strategic-insights",
"image_url": "https://static.gurufocus.com/logos/0C000009LF.png?5",
"language": "en",
"published_at": "2024-04-23T07:00:54.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "WASH",
"name": "Washington Trust Bancorp, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 129.11157,
"sentiment_score": 0.2176,
"highlights": [
{
"highlight": "A: Edward Handy, Chairman and CEO of <em>Washington</em> <em>Trust</em> <em>Bancorp</em>, confirmed that the settlement was related to the wealth management business.\n\nQ: Is the litigation surrounding those people leaving fully resolved with this settlement?\n\nA: Edward Handy confirmed that the settlement fully resolved the litigation.",
"sentiment": 0.4997,
"highlighted_in": "main_text"
},
{
"highlight": "A: Ronald Ohsberg, CFO of <em>Washington</em> <em>Trust</em> <em>Bancorp</em>, mentioned that the forecast includes an expectation of a net interest margin of 1.80% for the second quarter, with some uncertainty around Federal Reserve actions influencing future projections.\n\nQ: What are the expectations and means for the new deposit strategy you mentioned?",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Washington</em> <em>Trust</em> <em>Bancorp</em> <em>Inc</em> (WASH) Q1 2024 Earnings Call Transcript Highlights: Key Financial Metrics and Strategic Insights",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "3860875c-4f68-4cf2-84a6-66f6a1d0b9e1",
"title": "Dynex Capital Inc (DX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves and Financial Outcomes",
"description": "Total Economic Return: 2.1% for the quarterBook Value: $13.20 per common share at quarter endCapital Raised: $87 million in new capital deployed in February an",
"keywords": "GuruFocus, Article, News, GuruFocus Research, DX",
"snippet": "Release Date: April 22, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: Can we ...",
"url": "https://www.gurufocus.com/news/2415201/dynex-capital-inc-dx-q1-2024-earnings-call-transcript-highlights-strategic-moves-and-financial-outcomes",
"image_url": "https://static.gurufocus.com/logos/0C00000B24.png?5",
"language": "en",
"published_at": "2024-04-23T07:00:48.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "DX",
"name": "Dynex Capital, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Real Estate",
"match_score": 116.28001,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Dynex</em> <em>Capital</em> <em>Inc</em> (DX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves and Financial Outcomes",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "DX-PC",
"name": "Dynex Capital, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Real Estate",
"match_score": 116.260704,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Dynex</em> <em>Capital</em> <em>Inc</em> (DX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves and Financial Outcomes",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "7fd36e9f-2d64-4183-a1fc-8836a6b36099",
"title": "Simpson Manufacturing Co Inc (SSD) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Challenges with Strategic Adjustments",
"description": "Consolidated Net Sales: $530.6 million, a decrease of 0.7% year-over-year.North American Net Sales: $406.7 million, an increase of 0.1% year-over-year.European",
"keywords": "GuruFocus, Article, News, GuruFocus Research, SSD",
"snippet": "Release Date: April 22, 2024\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nQ & A Highlights\n\nQ: Can you...",
"url": "https://www.gurufocus.com/news/2415207/simpson-manufacturing-co-inc-ssd-q1-2024-earnings-call-transcript-highlights-navigating-market-challenges-with-strategic-adjustments",
"image_url": "https://static.gurufocus.com/logos/0C0000091Y.png?5",
"language": "en",
"published_at": "2024-04-23T07:02:50.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SSD",
"name": "Simpson Manufacturing Co., Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 120.45727,
"sentiment_score": 0.0772,
"highlights": [
{
"highlight": "<em>Simpson</em> <em>Manufacturing</em> <em>Co</em> <em>Inc</em> (SSD) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Challenges with Strategic Adjustments",
"sentiment": 0.0772,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "5c85a2f0-76a8-4344-8c1a-49a1aa1cf41c",
"title": "Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised",
"description": "Ad hoc announcement pursuant to Art. 53 LR Q1 net sales grew +11% with core operating income up +22% Key growth drivers continued strong sales momentum including Entresto , Cosentyx ,...",
"keywords": "Markets",
"snippet": "Ad hoc announcement pursuant to Art. 53 LR\n\nQ1 net sales grew +11% (cc 1 , +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers contin...",
"url": "https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-in-Q1-FY-2024-guidance-raised-46497087/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-04-23T05:00:10.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "0K9E.L",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 30.282383,
"sentiment_score": 0.384864,
"highlights": [
{
"highlight": "Giovanni Caforio as Chair of the Board of Directors at AGM 2025\n\n\n\n\n\nBasel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of <em>Novartis</em>, said:\n\n“<em>Novartis</em> continued our strong momentum with both sales growth and core margin expansion in Q1.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Strategy update\n\nOur focus\n\nIn 2023, <em>Novartis</em> completed its transformation into a “pure-play” innovative medicines business.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Financials\n\nFollowing the September 15, 2023, shareholder approval of the spin-off of Sandoz, <em>Novartis</em> reported its consolidated financial statements as “continuing operations” and “discontinued operations.”",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For further details see Note 3 “Significant transactions 2023 – Completion of the spin-off of the Sandoz business through a dividend in kind distribution to <em>Novartis</em> <em>AG</em> shareholders” and Note 12 “Discontinued operations” to the condensed interim consolidated financial statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The transaction aligns with <em>Novartis</em> strategic focus on oncology and strengthens our efforts in developing next-generation treatment options for cancer. Transaction is expected to close in Q2 2024\n\n\n\n<em>Novartis</em> has exercised its exclusive option to acquire IFM Due.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The acquisition gives <em>Novartis</em> full rights to IFM Due’s portfolio of STING antagonists, strengthening the company’s inflammatory diseases pipeline and building on our efforts to innovate new treatments for inflammation-driven conditions.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.\n\nAll product names appearing in italics are trademarks owned by or licensed to <em>Novartis</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Novartis</em>\n\n<em>Novartis</em> is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the <em>Novartis</em> website.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Important dates\n\n2-Jun-24 <em>Novartis</em> ASCO IR event (Chicago, US) 18-Jul-24 Second quarter & half year 2024 results 29-Oct-24 Third quarter & nine months 2024 results November 20-21, 2024 Meet <em>Novartis</em> Management 2024 (London, UK)\n\nPlease find full media release in English attached and on the following link:\n\nMedia release (PDF)\n\nGerman version is available",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
},
{
"symbol": "MOR",
"name": "MorphoSys AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.68247,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Data presented at MDA 2024 BD&L Announced the planned acquisition of <em>MorphoSys</em>, including pelabresib (late-stage BET inhibitor for myelofibrosis) and tulmimetostat (early-stage dual EZH2 and EZH1 inhibitor for solid tumors or lymphomas).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding results of ongoing clinical trials; or regarding potential future, pending or announced transactions, including the acquisition of <em>MorphoSys</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AG</em>; regarding potential future sales or earnings; or by discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or regarding our capital structure; or regarding the consequences of the spin-off of Sandoz and our transformation into a “pure-play",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVS",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 30.27632,
"sentiment_score": 0.384864,
"highlights": [
{
"highlight": "Giovanni Caforio as Chair of the Board of Directors at AGM 2025\n\n\n\n\n\nBasel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of <em>Novartis</em>, said:\n\n“<em>Novartis</em> continued our strong momentum with both sales growth and core margin expansion in Q1.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Strategy update\n\nOur focus\n\nIn 2023, <em>Novartis</em> completed its transformation into a “pure-play” innovative medicines business.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Financials\n\nFollowing the September 15, 2023, shareholder approval of the spin-off of Sandoz, <em>Novartis</em> reported its consolidated financial statements as “continuing operations” and “discontinued operations.”",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For further details see Note 3 “Significant transactions 2023 – Completion of the spin-off of the Sandoz business through a dividend in kind distribution to <em>Novartis</em> <em>AG</em> shareholders” and Note 12 “Discontinued operations” to the condensed interim consolidated financial statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The transaction aligns with <em>Novartis</em> strategic focus on oncology and strengthens our efforts in developing next-generation treatment options for cancer. Transaction is expected to close in Q2 2024\n\n\n\n<em>Novartis</em> has exercised its exclusive option to acquire IFM Due.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The acquisition gives <em>Novartis</em> full rights to IFM Due’s portfolio of STING antagonists, strengthening the company’s inflammatory diseases pipeline and building on our efforts to innovate new treatments for inflammation-driven conditions.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.\n\nAll product names appearing in italics are trademarks owned by or licensed to <em>Novartis</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Novartis</em>\n\n<em>Novartis</em> is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the <em>Novartis</em> website.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Important dates\n\n2-Jun-24 <em>Novartis</em> ASCO IR event (Chicago, US) 18-Jul-24 Second quarter & half year 2024 results 29-Oct-24 Third quarter & nine months 2024 results November 20-21, 2024 Meet <em>Novartis</em> Management 2024 (London, UK)\n\nPlease find full media release in English attached and on the following link:\n\nMedia release (PDF)\n\nGerman version is available",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
},
{
"symbol": "NOVN.SW",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "ch",
"type": "equity",
"industry": "Healthcare",
"match_score": 30.274807,
"sentiment_score": 0.384864,
"highlights": [
{
"highlight": "Giovanni Caforio as Chair of the Board of Directors at AGM 2025\n\n\n\n\n\nBasel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of <em>Novartis</em>, said:\n\n“<em>Novartis</em> continued our strong momentum with both sales growth and core margin expansion in Q1.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Strategy update\n\nOur focus\n\nIn 2023, <em>Novartis</em> completed its transformation into a “pure-play” innovative medicines business.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Financials\n\nFollowing the September 15, 2023, shareholder approval of the spin-off of Sandoz, <em>Novartis</em> reported its consolidated financial statements as “continuing operations” and “discontinued operations.”",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For further details see Note 3 “Significant transactions 2023 – Completion of the spin-off of the Sandoz business through a dividend in kind distribution to <em>Novartis</em> <em>AG</em> shareholders” and Note 12 “Discontinued operations” to the condensed interim consolidated financial statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The transaction aligns with <em>Novartis</em> strategic focus on oncology and strengthens our efforts in developing next-generation treatment options for cancer. Transaction is expected to close in Q2 2024\n\n\n\n<em>Novartis</em> has exercised its exclusive option to acquire IFM Due.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The acquisition gives <em>Novartis</em> full rights to IFM Due’s portfolio of STING antagonists, strengthening the company’s inflammatory diseases pipeline and building on our efforts to innovate new treatments for inflammation-driven conditions.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.\n\nAll product names appearing in italics are trademarks owned by or licensed to <em>Novartis</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Novartis</em>\n\n<em>Novartis</em> is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the <em>Novartis</em> website.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Important dates\n\n2-Jun-24 <em>Novartis</em> ASCO IR event (Chicago, US) 18-Jul-24 Second quarter & half year 2024 results 29-Oct-24 Third quarter & nine months 2024 results November 20-21, 2024 Meet <em>Novartis</em> Management 2024 (London, UK)\n\nPlease find full media release in English attached and on the following link:\n\nMedia release (PDF)\n\nGerman version is available",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
},
{
"symbol": "N1VS34.SA",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 30.27337,
"sentiment_score": 0.384864,
"highlights": [
{
"highlight": "Giovanni Caforio as Chair of the Board of Directors at AGM 2025\n\n\n\n\n\nBasel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of <em>Novartis</em>, said:\n\n“<em>Novartis</em> continued our strong momentum with both sales growth and core margin expansion in Q1.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Strategy update\n\nOur focus\n\nIn 2023, <em>Novartis</em> completed its transformation into a “pure-play” innovative medicines business.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Financials\n\nFollowing the September 15, 2023, shareholder approval of the spin-off of Sandoz, <em>Novartis</em> reported its consolidated financial statements as “continuing operations” and “discontinued operations.”",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For further details see Note 3 “Significant transactions 2023 – Completion of the spin-off of the Sandoz business through a dividend in kind distribution to <em>Novartis</em> <em>AG</em> shareholders” and Note 12 “Discontinued operations” to the condensed interim consolidated financial statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The transaction aligns with <em>Novartis</em> strategic focus on oncology and strengthens our efforts in developing next-generation treatment options for cancer. Transaction is expected to close in Q2 2024\n\n\n\n<em>Novartis</em> has exercised its exclusive option to acquire IFM Due.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The acquisition gives <em>Novartis</em> full rights to IFM Due’s portfolio of STING antagonists, strengthening the company’s inflammatory diseases pipeline and building on our efforts to innovate new treatments for inflammation-driven conditions.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.\n\nAll product names appearing in italics are trademarks owned by or licensed to <em>Novartis</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Novartis</em>\n\n<em>Novartis</em> is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the <em>Novartis</em> website.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Important dates\n\n2-Jun-24 <em>Novartis</em> ASCO IR event (Chicago, US) 18-Jul-24 Second quarter & half year 2024 results 29-Oct-24 Third quarter & nine months 2024 results November 20-21, 2024 Meet <em>Novartis</em> Management 2024 (London, UK)\n\nPlease find full media release in English attached and on the following link:\n\nMedia release (PDF)\n\nGerman version is available",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
},
{
"symbol": "NVSEF",
"name": "Novartis AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 30.2726,
"sentiment_score": 0.384864,
"highlights": [
{
"highlight": "Giovanni Caforio as Chair of the Board of Directors at AGM 2025\n\n\n\n\n\nBasel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of <em>Novartis</em>, said:\n\n“<em>Novartis</em> continued our strong momentum with both sales growth and core margin expansion in Q1.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Strategy update\n\nOur focus\n\nIn 2023, <em>Novartis</em> completed its transformation into a “pure-play” innovative medicines business.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Financials\n\nFollowing the September 15, 2023, shareholder approval of the spin-off of Sandoz, <em>Novartis</em> reported its consolidated financial statements as “continuing operations” and “discontinued operations.”",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For further details see Note 3 “Significant transactions 2023 – Completion of the spin-off of the Sandoz business through a dividend in kind distribution to <em>Novartis</em> <em>AG</em> shareholders” and Note 12 “Discontinued operations” to the condensed interim consolidated financial statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The transaction aligns with <em>Novartis</em> strategic focus on oncology and strengthens our efforts in developing next-generation treatment options for cancer. Transaction is expected to close in Q2 2024\n\n\n\n<em>Novartis</em> has exercised its exclusive option to acquire IFM Due.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The acquisition gives <em>Novartis</em> full rights to IFM Due’s portfolio of STING antagonists, strengthening the company’s inflammatory diseases pipeline and building on our efforts to innovate new treatments for inflammation-driven conditions.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.\n\nAll product names appearing in italics are trademarks owned by or licensed to <em>Novartis</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Novartis</em>\n\n<em>Novartis</em> is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the <em>Novartis</em> website.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Important dates\n\n2-Jun-24 <em>Novartis</em> ASCO IR event (Chicago, US) 18-Jul-24 Second quarter & half year 2024 results 29-Oct-24 Third quarter & nine months 2024 results November 20-21, 2024 Meet <em>Novartis</em> Management 2024 (London, UK)\n\nPlease find full media release in English attached and on the following link:\n\nMedia release (PDF)\n\nGerman version is available",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
},
{
"symbol": "MPSYF",
"name": "MorphoSys AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 8.681524,
"sentiment_score": 0,
"highlights": [
{
"highlight": "Data presented at MDA 2024 BD&L Announced the planned acquisition of <em>MorphoSys</em>, including pelabresib (late-stage BET inhibitor for myelofibrosis) and tulmimetostat (early-stage dual EZH2 and EZH1 inhibitor for solid tumors or lymphomas).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "express or implied discussions regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from any such products; or regarding results of ongoing clinical trials; or regarding potential future, pending or announced transactions, including the acquisition of <em>MorphoSys</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AG</em>; regarding potential future sales or earnings; or by discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or regarding our capital structure; or regarding the consequences of the spin-off of Sandoz and our transformation into a “pure-play",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "NVSD.BA",
"name": "NOVARTIS AG",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "N/A",
"match_score": 30.26557,
"sentiment_score": 0.384864,
"highlights": [
{
"highlight": "Giovanni Caforio as Chair of the Board of Directors at AGM 2025\n\n\n\n\n\nBasel, April 23, 2024 – commenting on Q1 2024 results, Vas Narasimhan, CEO of <em>Novartis</em>, said:\n\n“<em>Novartis</em> continued our strong momentum with both sales growth and core margin expansion in Q1.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Strategy update\n\nOur focus\n\nIn 2023, <em>Novartis</em> completed its transformation into a “pure-play” innovative medicines business.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Financials\n\nFollowing the September 15, 2023, shareholder approval of the spin-off of Sandoz, <em>Novartis</em> reported its consolidated financial statements as “continuing operations” and “discontinued operations.”",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "For further details see Note 3 “Significant transactions 2023 – Completion of the spin-off of the Sandoz business through a dividend in kind distribution to <em>Novartis</em> <em>AG</em> shareholders” and Note 12 “Discontinued operations” to the condensed interim consolidated financial statements.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The transaction aligns with <em>Novartis</em> strategic focus on oncology and strengthens our efforts in developing next-generation treatment options for cancer. Transaction is expected to close in Q2 2024\n\n\n\n<em>Novartis</em> has exercised its exclusive option to acquire IFM Due.",
"sentiment": -0.2263,
"highlighted_in": "main_text"
},
{
"highlight": "The acquisition gives <em>Novartis</em> full rights to IFM Due’s portfolio of STING antagonists, strengthening the company’s inflammatory diseases pipeline and building on our efforts to innovate new treatments for inflammation-driven conditions.",
"sentiment": 0.5719,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.\n\nAll product names appearing in italics are trademarks owned by or licensed to <em>Novartis</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Novartis</em>\n\n<em>Novartis</em> is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the <em>Novartis</em> website.",
"sentiment": 0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "Important dates\n\n2-Jun-24 <em>Novartis</em> ASCO IR event (Chicago, US) 18-Jul-24 Second quarter & half year 2024 results 29-Oct-24 Third quarter & nine months 2024 results November 20-21, 2024 Meet <em>Novartis</em> Management 2024 (London, UK)\n\nPlease find full media release in English attached and on the following link:\n\nMedia release (PDF)\n\nGerman version is available",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novartis</em> delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "a1177892-a292-41fb-8c69-008b5335ee3e",
"title": "Earnings call: AZZ Inc. hits record sales of $1.54 billion in fiscal 2024 By Investing.com",
"description": "Earnings call: AZZ Inc. hits record sales of $1.54 billion in fiscal 2024",
"keywords": "",
"snippet": "AZZ Inc . (NYSE: NYSE: ) has announced a record-breaking fiscal year 2024, with total sales reaching $1.54 billion, highlighting significant growth in its Metal...",
"url": "https://www.investing.com/news/stock-market-news/earnings-call-azz-inc-hits-record-sales-of-154-billion-in-fiscal-2024-93CH-3389817",
"image_url": "https://i-invdn-com.investing.com/news/LYNXNPEC0K08U_L.jpg",
"language": "en",
"published_at": "2024-04-22T23:38:57.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "AZZ",
"name": "AZZ Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 90.8252,
"sentiment_score": 0.56373,
"highlights": [
{
"highlight": "<em>AZZ</em> <em>Inc</em> . (NYSE: NYSE: ) has announced a record-breaking fiscal year 2024, with total sales reaching $1.54 billion, highlighting significant growth in its Metal Coatings and Precoat Metals segments. The company reported a 16.2% increase in sales and a substantial rise in net income from continuing operations to $101.6 million.",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AZZ</em> also reduced its debt by $115 million and received positive ratings from S&P Global and Fitch Ratings.\n\nKey Takeaways\n\n<em>AZZ</em> <em>Inc</em>.'s total sales for fiscal 2024 reached a record $1.54 billion, with Metal Coatings sales at $656 million and Precoat Metals sales at $881 million.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>AZZ</em> plans to invest $100 million to $120 million in capital expenditures for fiscal 2025, including the construction of a new aluminum coating plant.\n\nCompany Outlook\n\n<em>AZZ</em> intends to spend $100 to $120 million in fiscal 2025, focusing on the construction of a new aluminum coating plant.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Q&A Highlights\n\n<em>AZZ</em> has a 21% statutory tax rate and estimates a 3-4% tax rate for North America.\n\nAround 75% of production is contractually committed, with the possibility of more business from existing customers.\n\nThe company is not reliant on a single customer due to a seven-year contractual arrangement and diversified production capabilities.",
"sentiment": 0.2391,
"highlighted_in": "main_text"
},
{
"highlight": "In conclusion, <em>AZZ</em> <em>Inc</em>. is poised for continued growth with its strong fiscal performance and strategic investments. The company's leadership is confident in its ability to deliver strong results and generate substantial cash flow in the upcoming fiscal year.",
"sentiment": 0.9477,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro Insights\n\n<em>AZZ</em> <em>Inc</em>. (<em>NYSE</em>: <em>AZZ</em>) has demonstrated a remarkable financial performance in its latest fiscal year, with a robust increase in sales and net income. The company's strategic focus on growth is further substantiated by insights from InvestingPro.",
"sentiment": 0.872,
"highlighted_in": "main_text"
},
{
"highlight": "Additionally, <em>AZZ</em> has proven its commitment to shareholders by maintaining dividend payments for 15 consecutive years, which underlines its financial stability and investor-friendly approach.\n\nhere or remove ads . 3rd party Ad. Not an offer or recommendation by Investing.com.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "It's also worth noting that <em>AZZ</em> has seen a substantial price uptick over the last six months, with a 66.6% price total return, which reflects positively on the company's market performance and investor confidence.",
"sentiment": 0.8555,
"highlighted_in": "main_text"
},
{
"highlight": "For those interested in gaining deeper insights, there are additional InvestingPro Tips available, which can be accessed at InvestingPro <em>AZZ</em> if that was the case, does that suggest that maintaining guidance is actually more of a positive thing, because you are able to backfill some of that revenue?\n\nTom Ferguson: That is a good point, John.",
"sentiment": 0.9058,
"highlighted_in": "main_text"
},
{
"highlight": "Earnings call: <em>AZZ</em> <em>Inc</em>. hits record sales of $1.54 billion in fiscal 2024 By Investing.com",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "SPGI",
"name": "S&P Global Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 11.644218,
"sentiment_score": 0.4593,
"highlights": [
{
"highlight": "AZZ also reduced its debt by $115 million and received positive ratings from <em>S</em>&<em>P</em> <em>Global</em> and Fitch Ratings.\n\nKey Takeaways\n\nAZZ Inc.'s total sales for fiscal 2024 reached a record $1.54 billion, with Metal Coatings sales at $656 million and Precoat Metals sales at $881 million.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "The company received positive ratings from <em>S</em>&<em>P</em> <em>Global</em> and Fitch Ratings.\n\nAZZ plans to invest $100 million to $120 million in capital expenditures for fiscal 2025, including the construction of a new aluminum coating plant.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "5f852dd0-8970-4383-bd98-6f566e797624",
"title": "ADYEN : JP Morgan gives a Buy rating",
"description": "JP Morgan analyst Sandeep Deshpande maintains his Buy rating on the stock. The target price remains unchanged at EUR 1500.",
"keywords": "Markets",
"snippet": "Adyen N.V. is a technology company offering a single integrated platform that facilitates frictionless payments for merchants across channels and geographies. N...",
"url": "https://www.marketscreener.com/quote/stock/ADYEN-N-V-44211922/news/ADYEN-JP-Morgan-gives-a-Buy-rating-46499204/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-04-23T06:32:38.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "ADYEY",
"name": "Adyen N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 68.674736,
"sentiment_score": 0.184,
"highlights": [
{
"highlight": "<em>Adyen</em> <em>N.V</em>. is a technology company offering a single integrated platform that facilitates frictionless payments for merchants across channels and geographies. Net sales are distributed geographically as follows: Europe/Middle East/Africa (55.94%), North America (26.4%), Asia/Pacific (11.2%), and Latin America (6.5%).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ADYEN</em> : JP Morgan gives a Buy rating",
"sentiment": 0.368,
"highlighted_in": "title"
}
]
},
{
"symbol": "ADYYF",
"name": "Adyen N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 68.674736,
"sentiment_score": 0.184,
"highlights": [
{
"highlight": "<em>Adyen</em> <em>N.V</em>. is a technology company offering a single integrated platform that facilitates frictionless payments for merchants across channels and geographies. Net sales are distributed geographically as follows: Europe/Middle East/Africa (55.94%), North America (26.4%), Asia/Pacific (11.2%), and Latin America (6.5%).",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>ADYEN</em> : JP Morgan gives a Buy rating",
"sentiment": 0.368,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "3e35ca3b-bfb4-43fd-8e4c-dbd952834409",
"title": "CARL ZEISS MEDITEC AG : Receives a Sell rating from JP Morgan",
"description": "JP Morgan reiterate its Sell rating. The target price remains unchanged at EUR 70.",
"keywords": "Markets",
"snippet": "Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, vi...",
"url": "https://www.marketscreener.com/quote/stock/CARL-ZEISS-MEDITEC-AG-435842/news/CARL-ZEISS-MEDITEC-AG-Receives-a-Sell-rating-from-JP-Morgan-46499190/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-23T06:30:31.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "CZMWY",
"name": "Carl Zeiss Meditec AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 222.66669,
"sentiment_score": 0.49645,
"highlights": [
{
"highlight": "<em>Carl</em> <em>Zeiss</em> <em>Meditec</em> <em>AG</em> is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>CARL</em> <em>ZEISS</em> <em>MEDITEC</em> <em>AG</em> : Receives a Sell rating from JP Morgan",
"sentiment": 0.368,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "b6f0c853-86b5-4702-af87-1d65cfd57435",
"title": "Together Selects nCino to Revolutionise its Lending Business",
"description": "U.K. property lender to leverage nCino’s cloud-based platform across core servicesLONDON, April 23, 2024 -- nCino, Inc. , a pioneer in cloud banking for the global financial services industry,...",
"keywords": "Markets",
"snippet": "U.K. property lender to leverage nCino’s cloud-based platform across core services\n\nLONDON, April 23, 2024 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), a p...",
"url": "https://www.marketscreener.com/quote/stock/NCINO-109581178/news/Together-Selects-nCino-to-Revolutionise-its-Lending-Business-46499187/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-23T06:30:08.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "NCNO",
"name": "nCino, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 82.284225,
"sentiment_score": 0.290011,
"highlights": [
{
"highlight": "U.K. property lender to leverage nCino’s cloud-based platform across core services\n\nLONDON, April 23, 2024 (GLOBE NEWSWIRE) -- <em>nCino</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>NCNO</em>), a pioneer in cloud banking for the global financial services industry, today announced that Together, one of the UK’s leading property lenders, has selected nCino’s Cloud Banking Platform to revolutionise and future-proof its business.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "“We currently originate over £200 million in loans every month and, with <em>nCino</em>, we’re excited to scale and become more efficient through digital consolidation, enhanced risk management and a more modern customer experience.”",
"sentiment": 0.5209,
"highlighted_in": "main_text"
},
{
"highlight": "“We’re excited to partner with Together on this transformation programme,” said Charlie McIver, Managing Director – EMEA at <em>nCino</em>.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>nCino</em> is an integrated cloud-based solution that spans the origination lifecycle, from agreement and decision-in-principle through underwriting, offers and closing.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>nCino</em>\n\n<em>nCino</em> (<em>NASDAQ</em>: <em>NCNO</em>) is the worldwide leader in cloud banking.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Through its single software-as-a-service (SaaS) platform, <em>nCino</em> helps financial institutions serving corporate and commercial, small business, consumer, and mortgage customers modernize and more effectively onboard clients, make loans, manage the loan lifecycle, and open accounts.",
"sentiment": 0.6969,
"highlighted_in": "main_text"
},
{
"highlight": "Transforming how financial institutions operate through innovation, reputation and speed, <em>nCino</em> is partnered with more than 1,800 financial services providers globally. For more information, visit www.ncino.com.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Together Selects <em>nCino</em> to Revolutionise its Lending Business",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "4dee0271-86e1-4bd1-9a4f-0cbf7c318112",
"title": "Japan stocks higher at close of trade; Nikkei 225 up 0.28% By Investing.com",
"description": "Japan stocks higher at close of trade; Nikkei 225 up 0.28%",
"keywords": "",
"snippet": "Investing.com – Japan stocks were higher after the close on Tuesday, as gains in the , and sectors led shares higher.\n\nAt the close in Tokyo, the gained 0.28%...",
"url": "https://www.investing.com/news/stock-market-news/japan-stocks-higher-at-close-of-trade-nikkei-225-up-028-3390067",
"image_url": "https://i-invdn-com.investing.com/news/LYNXMPEB2F00C_L.jpg",
"language": "en",
"published_at": "2024-04-23T06:30:07.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "TKGSY",
"name": "Tokyo Gas Co.,Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Utilities",
"match_score": 53.465523,
"sentiment_score": -0.27385,
"highlights": [
{
"highlight": "(TYO: ) added 3.26% or 77.00 points to end at 2,443.50 and <em>Tokyo</em> <em>Gas</em> <em>Co</em>., <em>Ltd</em>. (TYO: ) was up 2.79% or 110.00 points to 4,046.00 in late trade.\n\nThe worst performers of the session were Toho Co., Ltd. (TYO: ), which fell 2.62% or 144.00 points to trade at 5,341.00 at the close.",
"sentiment": -0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Shares in <em>Tokyo</em> <em>Gas</em> <em>Co</em>., <em>Ltd</em>. (TYO: ) rose to 5-year highs; gaining 2.79% or 110.00 to 4,046.00.\n\nThe , which measures the implied volatility of Nikkei 225 options, was up 13.68% to 24.43 a new 52-week high.\n\nCrude oil for June delivery was up 0.20% or 0.16 to $82.06 a barrel.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TKGSF",
"name": "Tokyo Gas Co.,Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Utilities",
"match_score": 53.46553,
"sentiment_score": -0.27385,
"highlights": [
{
"highlight": "(TYO: ) added 3.26% or 77.00 points to end at 2,443.50 and <em>Tokyo</em> <em>Gas</em> <em>Co</em>., <em>Ltd</em>. (TYO: ) was up 2.79% or 110.00 points to 4,046.00 in late trade.\n\nThe worst performers of the session were Toho Co., Ltd. (TYO: ), which fell 2.62% or 144.00 points to trade at 5,341.00 at the close.",
"sentiment": -0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Shares in <em>Tokyo</em> <em>Gas</em> <em>Co</em>., <em>Ltd</em>. (TYO: ) rose to 5-year highs; gaining 2.79% or 110.00 to 4,046.00.\n\nThe , which measures the implied volatility of Nikkei 225 options, was up 13.68% to 24.43 a new 52-week high.\n\nCrude oil for June delivery was up 0.20% or 0.16 to $82.06 a barrel.",
"sentiment": 0.0772,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "bf4af79f-aaee-4504-b355-558f2df3d605",
"title": "Aerospace & Defense Telemetry Market to reach USD 3 Bn by 2032, Says Global Market Insights inc.",
"description": "Aerospace & Defense Telemetry Industry size is expected to register 7% CAGR between 2024 and 2032 propelled by the increasing demand for real-time data....",
"keywords": "Global Market Insights Inc., Aerospace & Defense Telemetry",
"snippet": "Selbyville, Delaware, April 23, 2024 (GLOBE NEWSWIRE) -- Aerospace & Defense Telemetry Market is likely to record USD 3 billion by 2032, as per a recent study b...",
"url": "https://www.globenewswire.com/news-release/2024/04/23/2867357/0/en/Aerospace-Defense-Telemetry-Market-to-reach-USD-3-Bn-by-2032-Says-Global-Market-Insights-inc.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/6a29379b-a16f-4ee6-9798-26bdadb816f3",
"language": "en",
"published_at": "2024-04-23T06:30:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "HON",
"name": "Honeywell International Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 24.125633,
"sentiment_score": 0.3182,
"highlights": [
{
"highlight": "., Northrop Grumman Corporation, <em>Honeywell</em> <em>International</em> <em>Inc</em>., Raytheon Technologies Corporation, Thales Group. R&D investments, strategic acquisitions, partnerships, and collaborations are actively undertaken by these players to complement existing offerings and address evolving customer needs.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "LHX",
"name": "L3Harris Technologies, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 28.489246,
"sentiment_score": 0.25,
"highlights": [
{
"highlight": "Aerospace & Defense Telemetry Market Players\n\nMajor companies in the aerospace & defense telemetry industry include BAE Systems plc, Lockheed Martin Corporation, <em>L3Harris</em> <em>Technologies</em>, <em>Inc</em>., Northrop Grumman Corporation, Honeywell International Inc., Raytheon Technologies Corporation, Thales Group.",
"sentiment": 0.25,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BAESY",
"name": "BAE Systems plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 26.941133,
"sentiment_score": 0.25,
"highlights": [
{
"highlight": "Aerospace & Defense Telemetry Market Players\n\nMajor companies in the aerospace & defense telemetry industry include <em>BAE</em> <em>Systems</em> <em>plc</em>, Lockheed Martin Corporation, L3Harris Technologies, Inc., Northrop Grumman Corporation, Honeywell International Inc., Raytheon Technologies Corporation, Thales Group.",
"sentiment": 0.25,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "BAESF",
"name": "BAE Systems plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 26.941133,
"sentiment_score": 0.25,
"highlights": [
{
"highlight": "Aerospace & Defense Telemetry Market Players\n\nMajor companies in the aerospace & defense telemetry industry include <em>BAE</em> <em>Systems</em> <em>plc</em>, Lockheed Martin Corporation, L3Harris Technologies, Inc., Northrop Grumman Corporation, Honeywell International Inc., Raytheon Technologies Corporation, Thales Group.",
"sentiment": 0.25,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "833c15d5-6109-4d73-bdd6-31cc6301bc59",
"title": "SFL - Acquisition of two LNG dual-fuel chemical carriers in combination with long term employment",
"description": "SFL Corporation Ltd. today announced that it has agreed to acquire two LNG dual-fuel 33,000 dwt chemical carriers. The vessels are built in 2022/2023 and fitted with stainless steel cargo tanks, and...",
"keywords": "Markets",
"snippet": "SFL Corporation Ltd. (NYSE: SFL) (“SFL” or the “Company”) today announced that it has agreed to acquire two LNG dual-fuel 33,000 dwt chemical carriers. ...",
"url": "https://www.marketscreener.com/quote/stock/SFL-CORPORATION-LTD-14366/news/SFL-Acquisition-of-two-LNG-dual-fuel-chemical-carriers-in-combination-with-long-term-employment-46499178/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-04-23T06:29:06.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "SFL",
"name": "SFL Corporation Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 53.767586,
"sentiment_score": 0.1366,
"highlights": [
{
"highlight": "<em>SFL</em> <em>Corporation</em> <em>Ltd</em>. (<em>NYSE</em>: <em>SFL</em>) (“SFL” or the “Company”) today announced that it has agreed to acquire two LNG dual-fuel 33,000 dwt chemical carriers. The vessels are built in 2022/2023 and fitted with stainless steel cargo tanks, and the aggregate purchase price is approximately $114 million.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "April 23, 2024\n\nThe Board of Directors\n\n<em>SFL</em> <em>Corporation</em> <em>Ltd</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "SOIEF",
"name": "Stolt-Nielsen Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 45.38628,
"sentiment_score": 0.333225,
"highlights": [
{
"highlight": "SFL has arranged long term employment for the vessels with affiliates of Stolt Tankers, a subsidiary of the world-leading chemical logistics company <em>Stolt</em>-<em>Nielsen</em> <em>Limited</em> (“<em>Stolt</em>-<em>Nielsen</em>”).\n\nThe Company expects to take delivery of the vessels between June and August this year and both vessels will be employed for a minimum of eight years.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We are excited to build a new relationship with <em>Stolt</em>-<em>Nielsen</em> who has a market leading position in the logistics for sophisticated chemicals. The market dynamics for stainless-steel chemical tankers are also very favorable now, with steady underlying growth in demand, ageing fleet and a limited orderbook.",
"sentiment": 0.8925,
"highlighted_in": "main_text"
},
{
"highlight": "Commenting on the transaction, Udo Lange, Chief Executive Officer, <em>Stolt</em>-<em>Nielsen</em> said “I’m pleased to announce our new partnership with SFL Corporation on two modern chemical tankers.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "As a leading liquid logistics provider, it is critical <em>Stolt</em>-<em>Nielsen</em> balances capital allocation across all our businesses to drive further improvements in our industry leading customer service offering and reliability.”\n\n\n\nApril 23, 2024\n\nThe Board of Directors\n\nSFL Corporation Ltd.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "08af9f7e-ffd6-4761-94ee-eb46c0d4f838",
"title": "UBS AG : Barclays reiterates its Sell rating",
"description": "Barclays's analyst Krishnendra Dubey maintains his Sell rating on the stock. The target price has been revised upwards and is now set at CHF 21, compared with CHF 20 previously.",
"keywords": "Markets",
"snippet": "UBS Group AG is a holding company that operates in four areas: - wealth management (54.3% of revenues); - investment banking (24.9%); - retail and corporate ban...",
"url": "https://www.marketscreener.com/quote/stock/UBS-GROUP-AG-19156942/news/UBS-AG-Barclays-reiterates-its-Sell-rating-46499177/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-04-23T06:28:31.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "UBS",
"name": "UBS Group AG",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 36.584885,
"sentiment_score": 0.6908,
"highlights": [
{
"highlight": "<em>UBS</em> <em>Group</em> <em>AG</em> is a holding company that operates in four areas: - wealth management (54.3% of revenues); - investment banking (24.9%); - retail and corporate banking (12.3%); - asset management (8.5%). At the end of 2022, the group had CHF 525.1 billion in current deposits and CHF 387.2 billion in current loans.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 5377,
"sentiment_avg": 0.24737893133873587
}
]
}
Other details
Entity count
- 39,707